Hepatitis C News and Research

Latest Hepatitis C News and Research

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

Warning that "systemic underfunding of the Centers for Disease Control's Division of Viral Hepatitis puts millions of Americans' health and well-being at risk," the National Viral Hepatitis Roundtable today called on the Administration to work with Congress to take decisive action this year to fix the funding failure for viral hepatitis screening, surveillance, and early intervention programs.

17 Mar 2010

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Aegis Analytical Corp., the leading provider of Enterprise Manufacturing Intelligence software, announced today that Human Genome Sciences, Inc. will deploy Aegis’ Discoverant® as its data management, analytics and reporting solution in the scale-up and production of BENLYSTA™ (belimumab), an investigational drug for the treatment of systemic lupus that has successfully completed Phase 3 trials.

17 Mar 2010

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "Virological Response, Safety, and Pharmacokinetic Profile Following Single- and Multiple-Dose Administration of ACH-0141625 Protease Inhibitor to Healthy Volunteers and HCV Genotype-1 Patients" has been accepted as a late breaking poster presentation at the International Liver Congress™ 2010 being held April 14-18 in Vienna, Austria.

17 Mar 2010

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

Vertex Pharmaceuticals Incorporated today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.

17 Mar 2010

GAVI calls meeting with existing, potential donors

The GAVI Alliance has "asked existing and potential donors to a meeting in The Hague on March 25 and 26 to challenge them to 'make a strong impact' on childhood death rates," Reuters reports. "GAVI, which is supported by the World Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation and vaccine makers, says it has 40 percent of the $7 billion it needs between now and 2015 to help" immunize of millions of children in developing countries by 2015, according to the news service.

16 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity.

15 Mar 2010

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2009.

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

Medivir AB (Sweden) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).

12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Stason Pharmaceuticals to market Unilife's Unitract 1mL safety syringe in Japan, China and Taiwan

Unilife Corporation today announced that it has signed an exclusive five-year agreement with Stason Pharmaceuticals Inc, a U.S.-based pharmaceutical company, to market the Unitract™ 1mL safety syringe in Japan, China and Taiwan. Stason's Taiwan-based strategic alliance affiliate, Standard Chem. and Pharm. Co., LTD, will act as the primary distributor of the product within these designated territories.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

CDC survey finds HSV-2 infection as one of the most common STDs in U.S.

About 1 in 6 Americans (16.2 percent) between the ages of 14 and 49 is infected with herpes simplex virus type 2 (HSV-2), according to a national health survey released today by the Centers for Disease Control and Prevention. HSV-2 is a lifelong and incurable infection that can cause recurrent and painful genital sores.

10 Mar 2010

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

We have known for several years that Hepatitis C, a common cause of liver cirrhosis and cancer, also makes people three to four times more likely to develop Type 2 diabetes.

10 Mar 2010

Selective immunization of children may help reduce community transmission of influenza

Immunizing children and adolescents with inactivated influenza vaccine resulted in reduced rates of influenza in their community compared to a similar community in which children did not receive the vaccine, suggesting that vaccinating children may help prevent transmission of the virus and offer protection for unimmunized community residents, according to a study in the March 10 issue of JAMA.

10 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

International Liver Congress 2010: Achillion Pharmaceuticals' protease inhibitor abstract accepted for presentation

Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting

GAVI calls meeting with existing, potential donors

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

New MMMCC center improves patients’ access to medical marijuana

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Stason Pharmaceuticals to market Unilife's Unitract 1mL safety syringe in Japan, China and Taiwan

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

CDC survey finds HSV-2 infection as one of the most common STDs in U.S.

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

Selective immunization of children may help reduce community transmission of influenza

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in